This work demonstrated the utility of the synthetic PEG12-KL4 peptide to deliver siRNAs targeting both EGFR and PD-L1 simultaneously as a potential therapeutic strategy against NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.